CSI Market
Sign In | Register

Phathom Pharmaceuticals Inc (PHAT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PHAT Annual Cash Flow →
Reviewing cash flow figures over time highlights how Phathom Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-47.95
Depreciation & amortization0.22
Amortization of Other Assets1.76
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories3.29
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation15.15
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-0.83
Interest Expense Other-
Fair Value Adjustment Of Convertible Promissory Notes-
Other Expenses-
Accrued Interest On Revenue Interest Financing Liability-
Increase Decrease In Operating Right Of Use Asset And Lease Liabilities0.01
Capital Expenditures Incurred But Not Yet Paid-
Non Cash Final Interest Payment Fee3.50
Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock1.54
Accrued Payment- In- Kind Interest On Debt0.71
Accrued Interest On Revenue Interest Financing Liability Net Of Payments3.54
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable19.29
Increase (Decrease) in Accounts Payable and Accrued Liabilities20.27
Increase (Decrease) in Interest Payable, Net-0.40
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-7.05
Other Working Capital0.17
Other Noncash Income (Expense)-2.89
Other net0.00
Payments for (Proceeds from) Other Operating Activities-18.62
Discontinued operations0.00
Net Cash flow from Operating Activities-17.58
Investing Activities
Capital Expenditures-0.11
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.11
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings173.25
Long-term debt - repayments-229.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.14
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net121.85
Proceeds From Underwritten Public Offering Net-
Net Proceeds From Revenue Interest Financing Transaction-
Proceeds From Issuance Underwritten Public Offering121.97
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities70.19
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-17.68
Total Cash Flow52.51
4 historic quarters locked

Sign in to unlock the full Phathom Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Phathom Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-324867

Figures are derived from filed reports and may be restated. Historical data is subject to revision.